|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online June 5, 2007
doi: 10.1242/10.1242/jcs.03460
Research Article |
vβ3–ERK1/2-dependent S100A4-upregulated pathway
,
,
1 Laboratory of Molecular and Cellular Toxicology, Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan
2 Angiogenesis Research Center, National Taiwan University, Taipei, Taiwan
3 Department of Surgery, National Taiwan University Hospital, Taipei 100, Taiwan
4 Graduate Institute of Cancer Biology, College of Medicine, China Medical University, Taichung 404, Taiwan
5 Center for Molecular Medical, China Medical University Hospital, Taichung 404, Taiwan
6 Department of Biotechnology and Bioinformatics, Asia University, Taichung 41354, Taiwan
7 Division of Cancer Research, National Health Research Institutes, Taipei 10016, Taiwan
Authors for correspondence (e-mails: kingjen{at}ntu.edu.tw; kuominliang{at}ntu.edu.tw)
Accepted 11 April 2007
Connective tissue growth factor (CTGF) expression is elevated in advanced stages of breast cancer, but the regulatory role of CTGF in invasive breast cancer cell phenotypes is unclear. Presently, overexpression of CTGF in MCF-7 cells (MCF-7/CTGF cells) enhanced cellular migratory ability and spindle-like morphological alterations, as evidenced by actin polymerization and focal-adhesion-complex aggregation. Reducing the CTGF level in MDA-MB-231 (MDA231) cells by antisense CTGF cDNA (MDA231/AS cells) impaired cellular migration and promoted a change to an epithelial-like morphology. A neutralizing antibody against integrin
vβ3 significantly attenuated CTGF-mediated ERK1/2 activation and cellular migration, indicating that the integrin-
vβ3–ERK1/2 signaling pathway is crucial in mediating CTGF function. Moreover, the cDNA microarray analysis revealed CTGF-mediated regulation of the prometastatic gene S100A4. Transfection of MCF-7/CTGF cells with AS-S100A4 reversed the CTGF-induced cellular migratory ability, whereas overexpression of S100A4 in MDA231/AS cells restored their high migratory ability. Genetic and pharmacological manipulations suggested that the CTGF-mediated S100A4 upregulation was dependent on ERK1/2 activation, with expression levels of CTGF and S100A4 being closely correlated with human breast tumors. We conclude that CTGF plays a crucial role in migratory/invasive processes in human breast cancer by a mechanism involving activation of the integrin-
vβ3–ERK1/2–S100A4 pathway.
Key words: Connective tissue growth factor, Breast cancer, ERK1/2, Integrin, S100A4, Cell migration, F-actin
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Li, T. Sanchez, A. Pappalardo, K. R. Lynch, T. Hla, and F. Ferrer Induction of Antiproliferative Connective Tissue Growth Factor Expression in Wilms' Tumor Cells by Sphingosine-1-Phosphate Receptor 2 Mol. Cancer Res., October 1, 2008; 6(10): 1649 - 1656. [Abstract] [Full Text] [PDF] |
||||